Katherine Xu, William Blair (2/13/13) "We believe the chance for success is higher for OncoGeneX Pharmaceuticals Inc.'s Synergy (custirsen plus Taxotere) study than the other phase 3 studies conducted to date in this setting, based on robust data observed from custirsen's randomized phase 2 study. Should top line data from the company's phase 3 Synergy study demonstrate a statistically significant improvement in overall survival versus Taxotere alone, we believe the combination could grab substantial share of the front line as well as second line chemotherapy settings; top line data from Synergy are anticipated during Q4/13."
Douglas Loe, Byron Capital Markets (2/12/13) "OncoGenex Pharmaceuticals Inc. will be starting a new phase 2 cancer study testing its ISIS-licensed heat shock protein 27 (Hsp27)-targeted antisense drug OGX-427; this will be a 200-patient second-line active-controlled metastatic bladder cancer study combining OGX-427 with the taxane drug docetaxel (Sanofi's Taxotere), the same drug with which OncoGenex's lead antisense drug OGX-011 is combined in an ongoing pivotal prostate cancer trial. . .we view the commencement of Borealis-2 as positive to OncoGenex's phase II/III oncology pipeline, a pipeline in which OGX-427 is growing in status with now five phase I/II oncology trials."
Box, I agree. We know 011 is last standing candidate for agent to work with Taxotere in prostate space. 011 is biological agent designed to work with Taxotere. We expect evidence of success in survival but the landscape has changed with MDVN and Cougar drugs. So primary question is whether the drug will be approved, and as some have pointed here recently, there may be a related and equally important question of the effectiveness of 011 in this new landscape.
I have no idea what I will do but at least we have months to decide.